Advertisement
UK markets close in 5 hours 14 minutes

  • FTSE 100

    8,093.01
    +52.63 (+0.65%)
     

  • FTSE 250

    19,725.07
    +5.70 (+0.03%)
     

  • AIM

    755.40
    +0.71 (+0.09%)
     

  • GBP/EUR

    1.1669
    +0.0024 (+0.21%)
     

  • GBP/USD

    1.2518
    +0.0055 (+0.44%)
     

  • Bitcoin GBP

    50,967.95
    -2,031.07 (-3.83%)
     

  • CMC Crypto 200

    1,361.60
    -20.97 (-1.52%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    82.82
    +0.01 (+0.01%)
     

  • GOLD FUTURES

    2,337.40
    -1.00 (-0.04%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,979.01
    -109.69 (-0.61%)
     

  • CAC 40

    8,044.68
    -47.18 (-0.58%)
     
Stock:

Trending tickers

Microsoft, Google, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

EXCLUSIVE -Shire closer to deal to buy Baxalta -sources

Reuters - UK Focus

NEW YORK, Dec 22 (Reuters) - Drug maker Shire Plc (Xetra: S7E.DE - news) has made a new acquisition offer that is roughly in line with Baxalta International Inc's valuation expectations, making a deal in the coming weeks likely, according to people familiar with the matter.

While the exact terms of the deal could not be learned, Shire has added enough cash to its previous all-stock offer for the negotiations to advance, the people said. Baxalta (Berlin: 9BX.BE - news) would be valued in excess of $30 billion in any deal, one of the people added.

The sources asked not to be identified because the negotiations are confidential. Baxalta and Shire spokespeople offered no comment. (Reporting by Carl O'Donnell in New York and Pamela Barbaglia in London; Editing by James Dalgleish)